Monthly Newsletter

SMi is proud to present its 6th annual conference on COPD taking place from the 20th - 21st October 2014 in Central London. 

With the global COPD market forecasted to reach a value of $15.6 billion by 2019, COPD 2014 comes at a perfect time to provide the industry with a niche platform for discussion and a forum to learn from key visionaries in the field of COPD. 

The latest instalment in the successful series has evolved to include topical and current sessions, such as Patient Care and The Future of COPD, as well as presenting attendees with in-depth information on exacerbation and comorbidities, ensuring a successful clinical trial design and challenges in drug development and market access. 

“Fast and cost effective development of drugs that help to improve significantly the quality of life of patients requires the intensified collaboration of industry, academia, clinical research and regulators agencies. Working in the field of biomarkers at the interface of pre-clinical and clinical research makes this an everyday requirement. The 6th COPD conference will bring together key opinion leaders from different stakeholders and will therefore foster this collaboration, especially by providing a very focused agenda.” Thomas Schlange, Senior Biomarker Expert, Bayer

KEY SPEAKERS INCLUDE:

• Marcello Milano, Executive Global Regulatory Affairs, Chiesi

• Thomas Schlange, Senior Biomarker Expert, Bayer

• Mercedes Prior, Head of Global Market Access, Almirall

• Carla Bauer, Investigator, Novartis

• Jan-Anders Karlsson, CEO, Verona Pharma

• Ewan Walters, Medical Director, Teva

• Rosa Lamarca, Head of Clinical Statistics, Almirall

• Robert Wilson, Consultant Physician Lung Division, Royal Brompton Hospital

• Abebaw Yohannes, Reader in Physiotherapy, Manchester Metropolitan University

• Jim & Mary Nelson, Patient, Caregiver, Representatives of COPD Foundation and EFFORTS Online Support Group

WHY ATTEND THIS EVENT:

• Understand the regulatory aspects of COPD, both from regulatory bodies and the industry

• Examine the current challenges to modelling exacerbations in COPD using animal models

• Evaluate COPD and comorbidities

• Understand the link between COPD and anxiety and depression

• Review the challenges in clinical trial designs and in drug development

• Discover the importance of putting the patient at the centre of everything

• Gain insight from real life story of a lung transplant patient

For further information click here